Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 32, Issue 31, 2014, Pages 3553-3558

  Paganin, Maddalena ^a   Fabbri, Giulia ^a   Conter, Valentino ^b   Barisone, Elena ^d   Polato, Katia ^a   Cazzaniga, Giovanni ^c   Giraldi, Eugenia ^e   Fagioli, Franca ^d   Aricò, Maurizio ^e   Valsecchi, Maria Grazia ^c   Basso, Giuseppe ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^e Ospedale Papa Giovanni XXIII di Bergamo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; STEROID; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; B CELL LEUKEMIA; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CONSOLIDATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FOLLOW UP; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; ITALY; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PATIENT MONITORING; POSTINDUCTION CHEMOTHERAPY; PREDICTIVE VALUE; PRESCHOOL CHILD; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; T CELL LEUKEMIA; CLINICAL TRIAL; CONTROLLED STUDY; INFANT; MULTICENTER STUDY; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; ITALY; MALE; METHOTREXATE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REAL-TIME POLYMERASE CHAIN REACTION; REMISSION INDUCTION; STEROIDS; TREATMENT OUTCOME;

EID: 84911918493     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.0698     Document Type: Article

References (30)

1. Pui CH, Mullighan CG, Evans WE, et al: Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there? Blood 120:1165-1174, 2012
2. Bhojwani D, Pui CH: Relapsed childhood acute lymphoblastic leukaemia. Lancet Oncol 14:e205-e217, 2013
3. Tallen G, Ratei R, Mann G, et al: Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: Results of trial ALL-REZ BFM 90. J Clin Oncol 28:2339-2347, 2010
4. Cavé H, van der Werff ten Bosch J, Suciu S, et al: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia: European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 339:591-598, 1998
5. van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al: Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352:1731-1738, 1998
6. Conter V, Bartram CR, Valsecchi MG, et al: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115:3206-3214, 2010
7. Schrappe M: Minimal residual disease: Optimal methods, timing, and clinical relevance for an individual patient. Hematology Am Soc Hematol Educ Program 2012:137-142, 2012
8. Campana D: Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010:7-12, 2010
9. Garand R, Beldjord K, Cavé H, et al: Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: A French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL. Leukemia 27:370-376, 2013
10. Schrappe M, Valsecchi MG, Bartram CR, et al: Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study. Blood 118:2077-2084, 2011
11. Eckert C, Henze G, Seeger K, et al: Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol 31:2736-2742, 2013
12. Denys B, van der Sluijs-Gelling AJ, Homburg C, et al: Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 27:635-641, 2013
13. Eckert C, Biondi A, Seeger K, et al: Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 358:1239-1241, 2001
14. Gaipa G, Cazzaniga G, Valsecchi MG, et al: Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica 97:1582-1593, 2012
15. Coustan-Smith E, Behm FG, Sanchez J, et al: Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 351:550-554, 1998
16. Borowitz MJ, Devidas M, Hunger SP, et al: Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group study. Blood 111:5477-5485, 2008
17. Flohr T, Schrauder A, Cazzaniga G, et al: Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 22:771-782, 2008
18. Pui CH, Campana D: New definition of remission in childhood acute lymphoblastic leukemia. Leukemia 14:783-785, 2000
19. Aricó M, Baruchel A, Bertrand Y, et al: The Seventh International Childhood Acute Lymphoblastic Leukemia Workshop Report: Palermo, Italy, January 29-30, 2005. Leukemia 19:1145-1152, 2005
20. Raff T, Gökbuget N, Lüschen S, et al: Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: Data from the GMALL 06/99 and 07/03 trials. Blood 109:910-915, 2007
21. Lo Coco F, Diverio D, Avvisati G, et al: Therapy of molecular relapse in acute promyelocytic leukemia. Blood 94:2225-2229, 1999
22. Pongers-Willemse MJ, Seriu T, Stolz F, et al: Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: Report of the BIOMED-1 CONCERTED ACTION-Investigation of minimal residual disease in acute leukaemia. Leukemia 13:110-118, 1999
23. van Dongen JJ, Langerak AW, Brüggemann M, et al: Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257-2317, 2003
24. van der Velden VH, Cazzaniga G, Schrauder A, et al: Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia 21:604-611, 2007
25. Marshall GM, Haber M, Kwan E, et al: Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. J Clin Oncol 21:704-709, 2003
26. Aricò M, Conter V, Valsecchi MG, et al: Importance of minimal residual disease testing during the second year of disease: Still no answer? J Clin Oncol 21:4463-4464, 2003
27. Gökbuget N, Kneba M, Raff T, et al: Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 120:1868-1876, 2012
28. Hong D, Gupta R, Ancliff P, et al: Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science 319:336-339, 2008
29. Zaliova M, Fronkova E, Krejcikova K, et al: Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: Implications for residual disease monitoring. Leukemia 23:944-951, 2009
30. Rubnitz JE, Hijiya N, Zhou Y, et al: Lack of benefit of early detection of relapse after completion of therapy for acute lymphoblastic leukemia. Pediatr Blood Cancer 44:138-141, 2005